Skip to main navigation Skip to search Skip to main content

The Suprasellar Meningioma Patient-Reported Outcome Survey: a disease-specific patient-reported outcome measure for resection of suprasellar meningioma

  • Adham M. Khalafallah
  • , Maureen Rakovec
  • , Katemanee Burapachaisri
  • , Shirley Fung
  • , Sharon L. Kozachik
  • , Benita Valappil
  • , Hussam Abou-Al-Shaar
  • , Eric W. Wang
  • , Carl H. Snyderman
  • , Georgios A. Zenonos
  • , Paul A. Gardner
  • , Mustafa K. Baskaya
  • , David Dornbos
  • , Garret Choby
  • , Edward C. Kuan
  • , Christopher Roxbury
  • , Jonathan B. Overdevest
  • , David A. Gudis
  • , Victoria S. Lee
  • , Joshua M. Levy
  • Andrew Thamboo, Rodney J. Schlosser, Judy Huang, Chetan Bettegowda, Nyall R. London, Nicholas R. Rowan, Albert W. Wu, Debraj Mukherjee

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

OBJECTIVE Suprasellar meningioma resection via either the transcranial approach (TCA) or the endoscopic endonasal approach (EEA) is an area of controversy and active evaluation. Skull base surgeons increasingly consider patient-reported outcomes (PROs) when choosing an approach. No PRO measure currently exists to assess quality of life for suprasellar meningiomas. METHODS Adult patients undergoing suprasellar meningioma resection between 2013 and 2019 via EEA (n = 14) or TCA (n = 14) underwent semistructured interviews. Transcripts were coded using a grounded theory approach to identify themes as the basis for a PRO measure that includes all uniquely reported symptoms. To assess content validity, 32 patients and 15 surgeons used a Likert scale to rate the relevance of items on the resulting questionnaire and the general Patient-Reported Outcomes Measurement Information System–29 (PROMIS29). The mean scores were calculated for all items and compared for TCA versus EEA patient cohorts by using unpaired t-tests. Items on either questionnaire with mean scores ≥ 2.0 from patients were considered meaningful and were aggregated to form the novel Suprasellar Meningioma Patient-Reported Outcome Survey (SMPRO) instrument. RESULTS Qualitative analyses resulted in 55 candidate items. Relative to patients who underwent the EEA, those who underwent the TCA reported significantly worse future outlook before surgery (p = 0.01), tiredness from medications 2 weeks after surgery (p = 0.001), and word-finding and memory difficulties 3 months after surgery (p = 0.05 and < 0.001, respectively). The items that patients who received a TCA were most concerned about included medication-induced lethargy after surgery (2.9 ± 1.3), blurry vision before surgery (2.7 ± 1.5), and difficulty reading due to blurry vision before surgery (2.7 ± 2.7). Items that patients who received an EEA were most concerned about included blurry vision before surgery (3.5 ± 1.3), difficulty reading due to blurry vision before surgery (2.4 ± 1.3), and problems with smell postsurgery (2.9 ± 1.3). Although surgeons overall overestimated how concerned patients were about questionnaire items (p < 0.0005), the greatest discrepancies between patient and surgeon relevance scores were for blurry vision pre- and postoperatively (p < 0.001 and < 0.001, respectively) and problems with taste postoperatively (p < 0.001). Seventeen meningioma-specific items were considered meaningful, supplementing 8 significant PROMIS29 items to create the novel 25-item SMPRO. CONCLUSIONS The authors developed a disease- and approach-specific measure for suprasellar meningiomas to compare quality of life by operative approach. If demonstrated to be reliable and valid in future studies, this instrument may assist patients and providers in choosing a personalized surgical approach.

Original languageEnglish
Pages (from-to)1551-1559
Number of pages9
JournalJournal of Neurosurgery
Volume136
Issue number6
DOIs
StatePublished - Jun 2022

Bibliographical note

Publisher Copyright:
© AANS 2022

Funding

Dr. Levy is supported by the National Institute of Biomedical Imaging and Bioengineering of the NIH under Award No. U54 HL-143541-02S2. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

FundersFunder number
National Institutes of Health (NIH)U54 HL-143541-02S2
National Institute of Biomedical Imaging and Bioengineering

    Keywords

    • oncology
    • quality of life
    • suprasellar meningioma
    • survey instrument

    ASJC Scopus subject areas

    • Surgery
    • Clinical Neurology

    Fingerprint

    Dive into the research topics of 'The Suprasellar Meningioma Patient-Reported Outcome Survey: a disease-specific patient-reported outcome measure for resection of suprasellar meningioma'. Together they form a unique fingerprint.

    Cite this